• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

byJames RoebkerandShaidah Deghan, MSc. MD
October 13, 2016
in Oncology, Surgery, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients undergoing prostatectomy for prostate cancer had significantly worse self-reported urinary and sexual function compared to radiotherapy and active monitoring, whereas those undergoing radiation therapy had significantly worse bowel function.

2. No significant differences were found between measures of general health between the three treatment options.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Management of prostate cancer based on prostate-specific antigen (PSA) levels is a controversial issue in men’s health. Early detection and treatment may provide individual and population health benefits, but current treatment options have a significant negative impact on a patient’s quality of life.

The ProtecT trial compared the effectiveness and health outcomes between the three most common current treatments – prostatectomy, radiotherapy, and active monitoring. The primary outcome was mortality which was reported elsewhere. This study reports the secondary outcome of interest – patient-reported outcomes – including measures of urinary, sexual, and bowel function, as well as measures of general health. Prostatectomy was found to have the greatest negative effect on urinary and sexual function, while radiotherapy had the greatest negative effect on bowel function. No significant differences between treatments were found in measures of general health. In conjunction with mortality data provided in the companion study, this provides an appreciation of the risk-benefit tradeoff in managing patients with prostate cancer.

This was a large, randomized trial that used validated patient-reported outcomes and had high response rates. This trial was also used in a larger trial evaluating the effectiveness of PSA for prostate cancer screening, increasing its generalizability. Significant limitations include poor representation of nonwhite males and the introduction of new diagnostic and therapeutic techniques since the trial’s inception.

RELATED REPORTS

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Exercise improves sexual function in men with prostate cancer  

Click to read the study, published today in NEJM

Relevant Reading: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer

In-Depth [randomized controlled trial]: In this randomized trial, population-based PSA screening identified 1643 men with localized prostate cancer that were randomized to active-monitoring (n = 545), radical prostatectomy (n = 553), or radiotherapy (n = 545). The primary outcome (mortality due to prostate cancer or treatment at 10 years), evaluated in a separate analysis, found low levels of death due to prostate cancer (1%) irrespective of treatment, but reported a significantly lower rate of disease progression in the prostatectomy and radiotherapy groups compared to active monitoring (p < 0.001).

The secondary outcome of interest (patient-reported outcomes) described in this study used validated questionnaires based on four domains – urinary function, sexual function, bowel function, and health-related quality of life. Questionnaires were completed at baseline, 6 months and 12 months, and then annually for the 6 years of follow-up. At all time points, prostatectomy had a greatest negative effect on urinary continence (p < 0.001) and erectile function (p < 0.001). In the prostatectomy, radiotherapy, and active monitoring groups, respectively, the rate of absorbent pad use was 17%, 4%, and 8% at 6 months. Sexual function (based on erection firmness and sexual function scores) was reduced from 67% at baseline to 12%, 22%, and 52%, respectively. Bowel function (based on loose and bloody stool reports) was significantly reduced in the radiotherapy group compared to the other treatments (p < 0.001). No significant differences in health-related quality of life measures were found at any time point.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: prostate cancer
Previous Post

New imaging technology can visualize cancer cells in patients [PreClinical]

Next Post

Advent of mammography associated with increased detection of smaller breast tumors

RelatedReports

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

July 8, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Exercise improves sexual function in men with prostate cancer  

May 24, 2025
BRAF V600E mutations linked with increased mortality in thyroid cancer
Oncology

Genome classifiers may aid prostate cancer risk stratification and treatment

January 20, 2025
Next Post
Spiculation of breast masses seen on mammography represents adipose invasion

Advent of mammography associated with increased detection of smaller breast tumors

Non-invasive prenatal testing linked to decreased diagnostic testing

Improving heat-shock protein levels shows efficacy against lysosomal storage diseases [PreClinical]

Paternal involvement in early childhood linked to improved developmental outcomes

Similar prostate cancer mortality with surgery, radiation, and active surveillance: The ProtecT trial

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.